PreOmics Announces Closing of Series B Financing to Accelerate Research, Development and Commercialization of Proteomics Tools and Consumables

MUNICH, Germany – January 18, 2022 – PreOmics GmbH, a Martinsried, Germany-based developer
of innovative automation and sample preparation tools and consumables for unbiased, deep
proteomics analysis by mass spectrometry, has raised €13.5m in a Series B financing round
provided by Bruker Corporation (Nasdaq: BRKR). PreOmics was founded in 2016 by Dr. Garwin
Pichler and Dr. Nils A. Kulak as a spin-out company from the laboratory of leading proteomics
researcher Professor Matthias Mann at the Max Planck Institute of Biochemistry in Martinsried.

PreOmics’ innovative sample processing technologies for mass spectrometry-based protein
analysis are complementary to Bruker’s high-performance scientific instruments, as well as to
proteomics mass spectrometry systems by other leading proteomics companies. Close
collaboration synergies are expected to broaden the market opportunities for both PreOmics’
BeatBox platform technologies and Bruker’s timsTOF 4D proteomics platform with more
complete, automated workflow solutions for academic and clinical researchers, for biomarker
discovery and diagnostics companies, as well as for CRO and biopharmaceutical companies.

Dr. Garwin Pichler, Co-Founder and Managing Director of PreOmics, commented: “We are excited
to increase R&D, marketing and sales investments, and are pleased to have Bruker as a collaborator
and major investor. Bruker shares our vision for advanced proteomic discovery processes for
everyone, and a commitment to accelerate PreOmics’ growth. Our existing and future customers
and partners will benefit from accelerated investments at PreOmics and from proteomics solution
synergies to extend our product offerings and global presence.”

Dr. Nils A. Kulak, Co-Founder and Managing Director of PreOmics, added: “We see a bright future
for PreOmics’ research, development and commercialization efforts, now accelerated by the Series
B primary investments and Bruker as partner and scientific collaborator. Our novel BeatBox technology is
seamlessly compatible with PreOmics’ proteomic sample preparation technologies and in combination with
the timsTOF Pro provides end-to-end workflows for processing of large tissue biobanks. Furthermore, we aim
to develop integrated and automated BeatBox-based workflow solutions for every experience level and
throughput need, while providing highest performance levels for unbiased, deep and comprehensive proteomics
research.”

In conjunction with the Series B financing, several early investors in PreOmics, such as High-Tech
Gründerfonds (HTGF) and Think.Health Ventures, as well as certain business angels, have
successfully sold their PreOmics shares to Bruker in a parallel secondary transaction, and Bruker is
now a majority investor in PreOmics. Financial details of the secondary transactions were not
disclosed.

Dr. Bernd Goergen, Partner with HTGF, commented on the successful exit: “The fact that our time
as a seed investor in Preomics has come to an end already after 5 years is a proof for the fantastic
performance of both the management and the extremely innovative technology. Thank you,
Garwin and Nils, for having us support a part of your journey. Joining forces with Bruker now paves
the way for setting gold standards in protein sample preparation and will make proteome analysis
easier and more reliable than ever.”

Dr. Michael Ruoff of Think.Health Ventures said: “Think.Health is grateful for having shared an
important part of PreOmics’ success story, which will continue also beyond our investment with the
great support by Bruker. We appreciate Garwin and Nils as exceptional scientists and visionary
entrepreneurs – a rare combination that we definitely need more of in Germany.”

Dr. Frank H. Laukien, President and CEO of Bruker Corporation, stated: “We are very pleased to
invest in PreOmics, a leading proteomics sample preparation, automation and consumables
company, with this Series B primary financing. By also acquiring a majority investment in PreOmics,
Bruker further expands its proteomics vision to include the unique PreOmics sample preparation
technologies, as well as more comprehensive, automated, robust and reproducible workflows and
consumables for translational, biomarker and biopharma proteomics research.”

About PreOmics GmbH

PreOmics empowers our clients in life sciences to establish biological knowledge through efficient,
reliable solutions and workflows that set the standard for protein analysis. Our team spirit, energy,
and commitment empower us to be both creative and quality focused – A trusted partner with
deeply rooted scientific experience. We envisage a future with revolutionary proteomic discovery
processes open for everyone. Tools that reveal hidden causes of diseases, ensure sustainable
nutrition, and provide diagnoses that enhance lives and society.

For more information, contact:

Dr. Garwin Pichler, Founder & Managing Director
PreOmics GmbH
Phone: +49 (0) 89 / 23 14 163 – 0
Email: info@preomics.com
Website: www.preomics.com
Address: Am Klopferspitz 19 | 82152 Planegg/Martinsried | Germany

About Think.Health Ventures

Think.Health invests as a boutique risk-taker in healthcare ventures. We continuously seek for
innovations and disruptive business models in digital healthcare, life sciences, pharmaceuticals and
biotechnology. For more information please visit www.think-health.de.

About High-Tech Gründerfonds

High-Tech Gründerfonds (HTGF) is a seed investor that finances high-potential, tech-driven startups.
With around EUR 900 million in total investment volume across three funds and an
international network of partners, HTGF has already helped forge more than 650 start-ups since
2005. Driven by their expertise, entrepreneurial spirit and passion, its team of experienced
investment managers and startup experts help guide the development of young companies.
HTGF’s focus is on high-tech start-ups in the fields of digital tech, industrial technology, life
sciences, chemistry and related business areas. To date, external investors have injected more than
EUR 3.5 billion into the HTGF portfolio via more than 1,800 follow-on financing rounds. HTGF has
also successfully sold interests in more than 150 companies.

Investors in this public-private partnership include the Federal Ministry for Economic Affairs and
Climate Action, KfW Capital, and Fraunhofer-Gesellschaft e.V., as well as the companies ALTANA,
BASF, BAYER, B.Braun, Boehringer Ingelheim, Robert Bosch, BÜFA, CEWE, Deutsche Bank, LANXESS, media + more venture Beteiligungs GmbH & Co. KG, PHOENIX CONTACT, QIAGEN, RWE Generation SE, SAP, Schufa, Schwarz Gruppe, STIHL, Thüga, Vector Informatik, WACKER and Wilh. Werhahn KG. www.htgf.de/en

Media Contact
High-Tech Gründerfonds Management GmbH
Stefanie Grüter, Head of Marketing & Communications
T.: +49 228 – 82300 – 188
s.grueter@htgf.de

Investor Contact
High-Tech Gründerfonds Management GmbH
Dr. Bernd Goergen, Partner
T.: +49 228 – 82300 – 136
b.goergen@htgf.de